EPZM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EPZM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Epizyme's annualized Gross Profit for the quarter that ended in Jun. 2022 was $89.31 Mil. Epizyme's average Total Assets over the quarter that ended in Jun. 2022 was $288.17 Mil. Therefore, Epizyme's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2022 was 30.99%.
The historical data trend for Epizyme's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epizyme Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Gross-Profit-to-Asset % | Get a 7-Day Free Trial | 3.69 | 7.68 | 6.80 | 2.38 | 7.06 |
Epizyme Quarterly Data | ||||||||||||||||||||
Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | |
Gross-Profit-to-Asset % | Get a 7-Day Free Trial | 11.07 | 3.74 | 10.86 | 8.11 | 30.99 |
For the Biotechnology subindustry, Epizyme's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Epizyme's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Epizyme's Gross-Profit-to-Asset % falls into.
Epizyme's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2021 is calculated as:
Gross-Profit-to-Asset % | = | Gross Profit (A: Dec. 2021 ) | / | ( (Total Assets (A: Dec. 2020 ) | + | Total Assets (A: Dec. 2021 )) | / count ) |
= | 26.929 | / | ( (473.573 | + | 289) | / 2 ) | |
= | 26.929 | / | 381.2865 | ||||
= | 7.06 % |
Epizyme's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2022 is calculated as:
Gross-Profit-to-Asset % | = | Gross Profit (Q: Jun. 2022 ) | / | ( (Total Assets (Q: Mar. 2022 ) | + | Total Assets (Q: Jun. 2022 )) | / count ) |
= | 89.312 | / | ( (312.186 | + | 264.159) | / 2 ) | |
= | 89.312 | / | 288.1725 | ||||
= | 30.99 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Jun. 2022) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Thank you for viewing the detailed overview of Epizyme's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffery Kutok | officer: Chief Scientific Officer | 784 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Jerald Korn | officer: Chief Operating Officer | 128 GORDON RD, NEWTON MA 02468 |
Joseph Beaulieu | officer: Corporate Controller | C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 |
Shefali Agarwal | officer: Chief Medical Officer | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Royalty Pharma Investments 2019 Icav | director, 10 percent owner | C/O RP MANAGEMENT, LLC 100 E. 59TH ST., 33RD FLOOR NEW YORK NY 10022 |
Pablo G. Legorreta | director | 110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022 |
Carol Stuckley | director | C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT |
Roy A Beveridge, | director | 500 W MAIN ST, LOUISVILLE KY 40202 |
David M Mott | director | 1119 ST. PAUL STREET, BALTIMORE MD 21202 |
Robert B Bazemore | director, officer: President & CEO | 33 HAYDEN AVE, LEXINGTON MA 02421 |
Matthew Ros | officer: Chief Operating Officer | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Paolo Tombesi | officer: Chief Financial Officer | 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807 |
Victoria Vakiener | officer: Chief Commercial Officer | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Carl Goldfischer | director | 161 WEST 61ST STREET, NEW YORK NY 10022 |
Rp Management, Llc | director | 110 EAST 59TH STREET SUITE 3300 NEW YORK NY 10022 |
From GuruFocus
By PRNewswire PRNewswire • 07-07-2022
By Business Wire Business Wire • 06-27-2022
By Business Wire Business Wire • 03-02-2022
By Business Wire Business Wire • 07-13-2022
By Business Wire Business Wire • 05-17-2022
By PRNewswire PRNewswire • 07-26-2022
By Business Wire Business Wire • 03-15-2022
By Business Wire Business Wire • 04-06-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By PRNewswire PRNewswire • 06-28-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.